Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharyn D Baker

Showing results (61-70 of 166) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Irinotecan pathway genotype analysis to predict pharmacokineticsRon H J Mathijssen, Sharon Marsh, Mats O Karlsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 daysKarl Bélanger, Malcolm Moore, Sharyn D Baker, et al.
Molecular Cancer Therapeutics|May 17, 2008
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemiaShuiying Hu, Hongmei Niu, Patton Minkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronideEric I Zimmerman, Shuiying Hu, Justin L Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumorsAntonio Jimeno, Jing Li, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderlyAlbert J ten Tije, Jaap Verweij, Michael A Carducci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Activated pregnenolone X-receptor is a target for ketoconazole and its analogsHongwei Wang, Haiyan Huang, Hao Li, et al.
Anti-Cancer Drugs|July 23, 2004
Limited cerebrospinal fluid penetration of docetaxelAlbert J ten Tije, Walter J Loos, Ming Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogueCarlton K K Lee, Eric K Rowinsky, Jing Li, et al.
Blood Advances|October 6, 2021
Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemiaMegan E Zavorka Thomas, Jae Yoon Jeon, Zahra Talebi, et al.
Pageof 17

Showing results (61-70 of 166) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Irinotecan pathway genotype analysis to predict pharmacokineticsRon H J Mathijssen, Sharon Marsh, Mats O Karlsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2002
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 daysKarl Bélanger, Malcolm Moore, Sharyn D Baker, et al.
Molecular Cancer Therapeutics|May 17, 2008
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemiaShuiying Hu, Hongmei Niu, Patton Minkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronideEric I Zimmerman, Shuiying Hu, Justin L Roberts, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumorsAntonio Jimeno, Jing Li, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderlyAlbert J ten Tije, Jaap Verweij, Michael A Carducci, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2007
Activated pregnenolone X-receptor is a target for ketoconazole and its analogsHongwei Wang, Haiyan Huang, Hao Li, et al.
Anti-Cancer Drugs|July 23, 2004
Limited cerebrospinal fluid penetration of docetaxelAlbert J ten Tije, Walter J Loos, Ming Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogueCarlton K K Lee, Eric K Rowinsky, Jing Li, et al.
Blood Advances|October 6, 2021
Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemiaMegan E Zavorka Thomas, Jae Yoon Jeon, Zahra Talebi, et al.
Pageof 17